{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:57:46Z","timestamp":1788904666765,"version":"build-2803163510"},"reference-count":0,"publisher":"Salvia Medical Sciences Ltd","license":[{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Galen Med J"],"abstract":"<jats:p>Psoriasis, a chronic immune-mediated skin disorder affecting 2-3% of the global population, is driven by a complex interplay of immune dysregulation, keratinocyte dysfunction, and genetic\/epigenetic alterations, with systemic comorbidities like psoriatic arthritis and cardiovascular disease amplifying its burden. Recent molecular insights, leveraging single-cell RNA sequencing and transcriptomics, have elucidated key pathogenic mechanisms, including GSDME-mediated pyroptosis, IL-23\/IL-17 axis activation, YAP1-driven proliferation, and epigenetic modulation via miR-106a-5p and lncRNA MEG3. These findings have spurred targeted therapies: IL-17 inhibitors (e.g., secukinumab) achieve rapid histologic remission, IL-23 inhibitors (e.g., risankizumab) offer sustained efficacy, and novel approaches like hyperforin, Deu@Cal microneedles, and concentrated growth factor (CGF) target diverse pathways in preclinical and early clinical settings. However, challenges persist, including adverse events (e.g., paradoxical eczema, MACEs), treatment resistance (81% biologic switching), and gaps in personalization despite promising biomarkers (e.g., calprotectin, miR-106a-5p). Future directions emphasize multi-omics integration, novel agents, and combination therapies to overcome these hurdles, aiming to transform psoriasis management into a paradigm of precision medicine.<\/jats:p>","DOI":"10.31661\/gmj.vi.3854","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T08:05:17Z","timestamp":1747987517000},"page":"e3854","source":"Crossref","is-referenced-by-count":1,"title":["Advances in the Molecular Pathogenesis and  Targeted Therapy of Psoriasis"],"prefix":"10.31661","author":[{"given":"Parivash","family":"Shokoufa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Aghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16705","published-online":{"date-parts":[[2025,5,11]]},"container-title":["Galen Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/journals.salviapub.com\/index.php\/gmj\/article\/download\/3854\/3166","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.salviapub.com\/index.php\/gmj\/article\/download\/3854\/3167","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.salviapub.com\/index.php\/gmj\/article\/download\/3854\/3166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T08:05:18Z","timestamp":1747987518000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.salviapub.com\/index.php\/gmj\/article\/view\/3854"}},"subtitle":["Molecular Pathogenesis of Psoriasis"],"short-title":[],"issued":{"date-parts":[[2025,5,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.31661\/gmj.vi.3854","relation":{},"ISSN":["2322-2379","2588-2767"],"issn-type":[{"value":"2322-2379","type":"electronic"},{"value":"2588-2767","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,11]]}}}